S02E01 Q&A - Damien Keogh: A New Language For Longevity | TLA
Medtech Innovation
•
16-Apr-2026
In this TLA S02 session, Damien Keogh explores why the real challenge in longevity may not be scientific discovery alone, but how the space is defined, measured, and evaluated. Drawing from drug discovery, venture capital, traditional Chinese medicine, evolutionary biology and AI, he offers a practical framework for separating vague longevity claims from truly actionable science - and makes the case that nature may already contain the molecules we are looking for.
Takeaways:
• Why many longevity claims sound exciting but fall apart when you ask for clear endpoints, mechanisms, and measurable benchmarks.
• How AI, polypharmacology, and natural-product research are opening new pathways for drug discovery and longevity science.
• Why the leaders and companies that define the standards of longevity may end up shaping the market itself.
Up Next in Medtech Innovation
-
S02E01 - Damien Keogh: A New Language...
In this TLA S02 session, Damien Keogh explores why the real challenge in longevity may not be scientific discovery alone, but how the space is defined, measured, and evaluated. Drawing from drug discovery, venture capital, traditional Chinese medicine, evolutionary biology and AI, he offers a pra...
-
The Longevity Arc: North American & E...
The future of longevity won’t be decided in laboratories alone. It will be shaped by leadership.
Join the Healthcare Business Network for an elevated, global conversation on human longevity. This session brings together leading voices from across the longevity ecosystem, spanning scientific rese...
-
Increasing Productivity and Success i...
Artificial intelligence is reshaping biotech, but separating promise from proof has never been more important.
Join us for a candid, peer-level conversation that brings together biotech leaders to examine how AI is applied across the drug discovery and development lifecycle. The focus is practic...
